The results of intravenous injection of novocain in asthma are very different according to the clinical type. In essential asthma, lasting improvements occur in about 50 % of the cases; more transitory results are observed in 30 %. In intricate asthma however, there are only 30 % of swift passing results. In dyspnaea by pulmonaris sclerosis, this medication is useless. A preliminary administration of luminal, per os, seems to improve the tolerance to novocain. Novocain does change neither the allergic state nor the neurovegetative desequilibrium ; it works by interrupting the pathologic reflex at the bronchopulmonary nervous endings.